Sana Biotechnology Inc (SANA)

$3.85 +0.06 (1.58%)
Market Cap 1.03B
Revenue (ttm) 0.00
Net Income (ttm) -266.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,497,754
Avg Vol 3,506,818
Day's Range N/A - N/A
Shares Out 266.37M
Stochastic %K 22%
Beta 1.96
Analysts Strong Sell
Price Target $8.71

Company Profile

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline consist of UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modi...

Industry: Biotechnology
Sector: Healthcare
Phone: 206 701 7914
Address:
188 East Blaine Street, Suite 400, Seattle, United States
BriOnH
BriOnH Feb. 13 at 6:41 PM
$SANA This author has been pretty good about reporting on Sana. +:"The clinical data not only suggest the possibility of a functional cure but also de-risk/validate its approach to escaping immune destruction, which could have applications across many indications." -:"That said, it will have to continue to dilute shareholders over the foreseeable future, possibly at a much higher share price." https://seekingalpha.com/article/4869957-sana-biotechnology-small-speculative-play
1 · Reply
BBraggHillBoys
BBraggHillBoys Feb. 13 at 3:23 PM
$SANA
0 · Reply
LoveRetailFroth
LoveRetailFroth Feb. 13 at 2:34 PM
$RXRX Good Morning ☕️ $AMLX $RARE $SANA
0 · Reply
OnlyInvestor
OnlyInvestor Feb. 11 at 6:16 PM
$SANA Please raise awareness on ISLET Act (S.3105) sponsored by Senators Mike Lee (R-UT) and Ted Budd (R-NC)… it’s a BIPARTISAN bill that is trying to classify donor & stem cell derived islet cells as ORGANS, not as drugs. For some reason they’re categorized as drugs right now, which makes it difficult for insurance companies to cover and for trials to be approved
0 · Reply
BriOnH
BriOnH Feb. 10 at 6:26 PM
$SANA Seems this could help speed things up. 👍🏼
3 · Reply
BBraggHillBoys
BBraggHillBoys Feb. 10 at 5:38 PM
$SANA
0 · Reply
LoveRetailFroth
LoveRetailFroth Feb. 10 at 2:30 PM
$AMLX Good Morning ☕️ $RXRX $SANA $RARE
0 · Reply
SKIJK
SKIJK Feb. 10 at 2:00 PM
$SANA Sana Biotechnology (SANA) closed the last trading session at $5, gaining 10.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $8.71 indicates a 74.2% upside potential. The average comprises seven short-term price targets ranging from a low of $6.00 to a high of $12.00, with a standard deviation of $2.43. While the lowest estimate indicates an increase of 20% from the current price level, the most optimistic estimate points to a 140% upside
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Feb. 10 at 6:50 AM
$IPSC $SANA $VRTX $CRSP $XBI Surprising how under the radar this one remains
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Feb. 8 at 4:16 PM
$IPSC vs $SANA vs $VRTX vs $CRSP vs other (?) for T1DM cure $XBI
0 · Reply
Latest News on SANA
Sana Biotechnology: A Small, Speculative Play

Feb 13, 2026, 3:24 AM EST - 15 hours ago

Sana Biotechnology: A Small, Speculative Play

Sana Biotechnology Stock: Promising T1D Science, But Wait For Dips

Jan 19, 2026, 7:40 AM EST - 25 days ago

Sana Biotechnology Stock: Promising T1D Science, But Wait For Dips

Sana Biotechnology, Inc. (SANA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 3:26 PM EST - 4 weeks ago

Sana Biotechnology, Inc. (SANA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Sana Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 4:26 PM EST - 5 weeks ago

Sana Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference

Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform

Dec 8, 2025, 9:00 AM EST - 2 months ago

Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform

Sana Biotechnology, Inc. (SANA) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 3, 2025, 5:03 PM EST - 2 months ago

Sana Biotechnology, Inc. (SANA) Presents at Evercore 8th Annual Healthcare Conference Transcript

Sana Biotechnology, Inc. (SANA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 2, 2025, 5:43 PM EST - 2 months ago

Sana Biotechnology, Inc. (SANA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Sana Biotechnology to Present at December 2025 Investor Conferences

Nov 24, 2025, 4:05 PM EST - 2 months ago

Sana Biotechnology to Present at December 2025 Investor Conferences

Sana Biotechnology: Scope Goes Beyond HIP-Modified Pancreatic Islet Cells For T1D

Oct 16, 2025, 5:09 PM EDT - 4 months ago

Sana Biotechnology: Scope Goes Beyond HIP-Modified Pancreatic Islet Cells For T1D

Sana Biotechnology: A Big Winner In Waiting? Maybe, But It Won't Happen Overnight

Oct 16, 2025, 4:18 PM EDT - 4 months ago

Sana Biotechnology: A Big Winner In Waiting? Maybe, But It Won't Happen Overnight

Sana Biotech Stock — The Next '100-Bagger'?

Oct 15, 2025, 12:15 PM EDT - 4 months ago

Sana Biotech Stock — The Next '100-Bagger'?

Sana Biotechnology, Inc. (SANA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 4:34 PM EDT - 5 months ago

Sana Biotechnology, Inc. (SANA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 5, 2025, 1:42 AM EDT - 5 months ago

Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sana Biotechnology, Inc. (SANA) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 2, 2025, 10:03 PM EDT - 5 months ago

Sana Biotechnology, Inc. (SANA) Presents At Citi's Biopharma Back To School Conference Transcript

IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies

Aug 28, 2025, 8:00 AM EDT - 6 months ago

IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies

FHTX IQV MRNA

Sana Biotechnology to Present at September 2025 Investor Conferences

Aug 26, 2025, 4:05 PM EDT - 6 months ago

Sana Biotechnology to Present at September 2025 Investor Conferences

Sana Biotechnology Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares

Aug 20, 2025, 4:05 PM EDT - 6 months ago

Sana Biotechnology Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares

Sana Biotechnology: Fundraising Triggers Major Sell-Off, I'm Still Intrigued

Aug 8, 2025, 2:58 PM EDT - 6 months ago

Sana Biotechnology: Fundraising Triggers Major Sell-Off, I'm Still Intrigued

Sana Biotechnology Announces Pricing of Public Offering

Aug 6, 2025, 11:24 PM EDT - 6 months ago

Sana Biotechnology Announces Pricing of Public Offering

Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Aug 6, 2025, 4:38 PM EDT - 6 months ago

Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 6, 2025, 7:00 AM EDT - 6 months ago

Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

MCRB

Sana Biotechnology Announces Publication in New England Journal of Medicine of Groundbreaking Clinical Data from Transplantation Without Immunosuppression of Hypoimmune-Modified, Insulin-Producing Islet Cells in Patient with Type 1 Diabetes

Aug 4, 2025, 11:35 AM EDT - 6 months ago

Sana Biotechnology Announces Publication in New England Journal of Medicine of Groundbreaking Clinical Data from Transplantation Without Immunosuppression of Hypoimmune-Modified, Insulin-Producing Islet Cells in Patient with Type 1 Diabetes

Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

Jun 23, 2025, 10:05 AM EDT - 8 months ago

Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

Two Biotech Stocks Poised For Big Moves On Monday

Jun 23, 2025, 7:39 AM EDT - 8 months ago

Two Biotech Stocks Poised For Big Moves On Monday

LCTX

Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions

Jun 9, 2025, 4:05 PM EDT - 8 months ago

Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions

Sana Biotechnology to Present at June 2025 Investor Conferences

May 28, 2025, 4:05 PM EDT - 9 months ago

Sana Biotechnology to Present at June 2025 Investor Conferences

Sana: HIP-Modified Islet Cells To Possibly Change Scope Of Type 1 Diabetes Treatment

May 19, 2025, 3:10 PM EDT - 9 months ago

Sana: HIP-Modified Islet Cells To Possibly Change Scope Of Type 1 Diabetes Treatment

The End Of The Diabetes Industry? This Small Cap Could Upend The Business Models of Pharma Giants

May 19, 2025, 11:57 AM EDT - 9 months ago

The End Of The Diabetes Industry? This Small Cap Could Upend The Business Models of Pharma Giants

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology

May 14, 2025, 2:50 PM EDT - 9 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology

Sana Biotechnology to Present at the BofA Securities 2025 Healthcare Conference

May 12, 2025, 4:05 PM EDT - 9 months ago

Sana Biotechnology to Present at the BofA Securities 2025 Healthcare Conference

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit - SANA

May 8, 2025, 5:45 AM EDT - 10 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit - SANA

BriOnH
BriOnH Feb. 13 at 6:41 PM
$SANA This author has been pretty good about reporting on Sana. +:"The clinical data not only suggest the possibility of a functional cure but also de-risk/validate its approach to escaping immune destruction, which could have applications across many indications." -:"That said, it will have to continue to dilute shareholders over the foreseeable future, possibly at a much higher share price." https://seekingalpha.com/article/4869957-sana-biotechnology-small-speculative-play
1 · Reply
BBraggHillBoys
BBraggHillBoys Feb. 13 at 3:23 PM
$SANA
0 · Reply
LoveRetailFroth
LoveRetailFroth Feb. 13 at 2:34 PM
$RXRX Good Morning ☕️ $AMLX $RARE $SANA
0 · Reply
OnlyInvestor
OnlyInvestor Feb. 11 at 6:16 PM
$SANA Please raise awareness on ISLET Act (S.3105) sponsored by Senators Mike Lee (R-UT) and Ted Budd (R-NC)… it’s a BIPARTISAN bill that is trying to classify donor & stem cell derived islet cells as ORGANS, not as drugs. For some reason they’re categorized as drugs right now, which makes it difficult for insurance companies to cover and for trials to be approved
0 · Reply
BriOnH
BriOnH Feb. 10 at 6:26 PM
$SANA Seems this could help speed things up. 👍🏼
3 · Reply
BBraggHillBoys
BBraggHillBoys Feb. 10 at 5:38 PM
$SANA
0 · Reply
LoveRetailFroth
LoveRetailFroth Feb. 10 at 2:30 PM
$AMLX Good Morning ☕️ $RXRX $SANA $RARE
0 · Reply
SKIJK
SKIJK Feb. 10 at 2:00 PM
$SANA Sana Biotechnology (SANA) closed the last trading session at $5, gaining 10.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $8.71 indicates a 74.2% upside potential. The average comprises seven short-term price targets ranging from a low of $6.00 to a high of $12.00, with a standard deviation of $2.43. While the lowest estimate indicates an increase of 20% from the current price level, the most optimistic estimate points to a 140% upside
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Feb. 10 at 6:50 AM
$IPSC $SANA $VRTX $CRSP $XBI Surprising how under the radar this one remains
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Feb. 8 at 4:16 PM
$IPSC vs $SANA vs $VRTX vs $CRSP vs other (?) for T1DM cure $XBI
0 · Reply
UgoGreg
UgoGreg Feb. 8 at 3:34 PM
$SANA https://youtu.be/b4CDDEB3OQo
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Feb. 8 at 2:50 PM
$IPSC vs $SANA vs $VXRT vs $CRSP vs other (?) for T1DM cure?? $XBI
1 · Reply
LoveRetailFroth
LoveRetailFroth Feb. 6 at 5:49 PM
$RXRX How are folks holding up😂 Lots of travels. Longs always win! $SANA $ARBE $RARE
1 · Reply
Patoun
Patoun Feb. 6 at 9:08 AM
$SANA I have 2 questions for $SANA experts: 1- why this -12.8% down yesterday ? I do not see any particular news here. 2- can someone help me understand the relatively high market cap for $SANA (around $1 Billion) ? As someone said below, it's a very early stage biopharma, with no products on the market or near to be in a foreseable future. In comparison, it's approximatively the same marketcap as $MLTX 's, which drug is in a far more advanced stage (and recently got FDA's Fast Track status) $BMEA as well is an early stage pharma, while valued only $80 Million, 12x less than SANA...Yet, Biomea's drugs' early datas are stunning. Thanks in advance. Please try answering in an non-agressive way. Just want to discsuss gently on the points above.
6 · Reply
discountcroesus1
discountcroesus1 Feb. 6 at 8:50 AM
$SANA
0 · Reply
mirko_papuga
mirko_papuga Feb. 6 at 12:45 AM
$SANA Ouch!
0 · Reply
BBraggHillBoys
BBraggHillBoys Feb. 5 at 7:36 PM
$SANA buying at these dips could produce a nice profit in 12 to 18 months...
0 · Reply
DividendHaven
DividendHaven Feb. 4 at 2:22 PM
$SANA is a clinical-stage biotech developing cell therapies for cancer and autoimmune diseases; it is a high-risk, early-stage company in the competitive cell therapy space.
0 · Reply
GLPHOTOX
GLPHOTOX Feb. 3 at 10:37 PM
$SANA any chart masters here to show where the support levels are at ?
3 · Reply
GLPHOTOX
GLPHOTOX Feb. 2 at 3:40 PM
$SANA Going Green !
0 · Reply
BBraggHillBoys
BBraggHillBoys Jan. 30 at 5:06 PM
$SANA
0 · Reply
Scrapps64
Scrapps64 Jan. 30 at 4:35 PM
$SANA Key Benefits: CDMOs provide access to advanced technology, expertise, and GMP (Good Manufacturing Practice) compliant facilities, which reduces capital investment and risks for pharmaceutical or biotech companies.
0 · Reply